AMMU representative said in this phase, the vaccine, developed by VietnameseNanogen Pharmaceutical Biotechnology JSC, will be tested on around 13,000volunteers aged between 18 and 74, in many localities nationwide.
Thethird phase, also the final one, aims to evaluate the effectiveness of thevaccine and each volunteer may only receive one jab of 25 mcg.
Director of the university Prof. Dr. Do Quyet showed his confidence in thesafety of Nano Covax vaccine with the positive results obtained from theprevious two trial phases.
Navo Covax vaccine started testing on humanson December 17 last year and has completed the second phase.
The first-phase trials showedthe vaccine was safe and vaccinated volunteers had antibodies against the UKvariant (B117).
Thesecond-phase ones were conducted on 560 volunteers dividedinto four groups, with 80 people injected with a placebo and three other groupsadministered with 25mcg, 50mcg, and 75mcg doses. However, only 554 receivedsecond shots because six people withdrew from the trial.
All of the vaccinated volunteers have developed antibodiesagainst COVID-19 at different levels.
Regarding the antibody index to neutralise the virus, peopleinjected with 25mcg dose got the highest index with more than 90 percent at14 days after the second shot and 42 days since the first jabs./.